Sanofi-Genzyme BioVentures hopes last week's investment in the $32.5 million first close of immunotherapy play Immune Design Corp.'s planned $49 million series C round will advance the fund's goal of filling parent Sanofi's pipeline.

Existing investor The Column Group and new investor Topspin Partners led the round. Existing investors Alta Partners, Versant Ventures, Osage Partners and ProQuest Investments also participated.